Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients – Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting – Results from the Non-Interventional Study PERFECT

References

• Hegen H, Auer M, Deisenhammer F. Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β. Expert Opin Drug Metab Toxicol. 2015;11(12):1803–1819. doi:10.1517/17425255.2015.1094055
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Oh J. Disease-modifying agents in multiple sclerosis. Handb Clin Neurol. 2014;122:465–501.
   PubMedGoogle Scholar
• Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord. 2011;4(5):281–296. doi:10.1177/1756285611413825
   PubMedGoogle Scholar
• Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009;6(1):1–16. doi:10.1517/17425240802650568
   PubMed Web of Science ®Google Scholar
• Baker DP, Pepinsky RB, Brickelmaier M, et al. PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):777–785. doi:10.1089/jir.2010.0092
   PubMed Web of Science ®Google Scholar
• Hu X, Miller L, Richman S, et al. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol. 2012;52(6):798–808. doi:10.1177/0091270011407068
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657–665. doi:10.1016/S1474-4422(14)70068-7
   PubMed Web of Science ®Google Scholar
• Menge T, Rehberg-Weber K, Taipale K, Nastos I, Jauß M. Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study. Ther Adv Neurol Disord. 2021;14:17562864211000461. doi:10.1177/17562864211000461
   Web of Science ®Google Scholar
• Newsome SD, Scott TF, Arnold DL, et al. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018;11:1756286418791143. doi:10.1177/1756286418791143
   Web of Science ®Google Scholar
• Balak DM, Hengstman GJ, Hajdarbegovic E, van den Brule RJ, Hupperts RM, Thio HB. Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study. BMC Neurol. 2013;13:146. doi:10.1186/1471-2377-13-146
   PubMed Web of Science ®Google Scholar
• Beer K, Müller M, Hew-Winzeler AM, et al. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BMC Neurol. 2011;11:144. doi:10.1186/1471-2377-11-144
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69–77. doi:10.1111/j.1468-1331.2010.03110.x
   PubMed Web of Science ®Google Scholar
• Moccia M, Palladino R, Russo C, et al. How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis. Expert Opin Drug Deliv. 2015;12(12):1829–1835. doi:10.1517/17425247.2015.1078789
   PubMed Web of Science ®Google Scholar
• Naismith RT, Hendin B, Wray S, et al. Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results. Mult Scler J Exp Transl Clin. 2019;5(1):2055217318822148.
   Google Scholar
• Buttmann M, Goebeler M, Toksoy A, et al. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol. 2005;168(1–2):175–182. doi:10.1016/j.jneuroim.2005.07.011
   PubMed Web of Science ®Google Scholar
• Hendin B, Huang D, Wray S, et al. Subcutaneous peginterferon beta-1a injection-site reaction experience and mitigation: delphi analysis of the ALLOW study. Neurodegener Dis Manag. 2017;7(1):39–47. doi:10.2217/nmt-2016-0032
   Web of Science ®Google Scholar
• Hinz A, Klaiberg A, Brähler E, König HH. [The Quality of Life Questionnaire EQ-5D: modelling and norm values for the general population]. Psychother Psychosom Med Psychol. 2006;56(2):42–48. doi:10.1055/s-2005-867061
   PubMed Web of Science ®Google Scholar
• Kersten P, Küçükdeveci AA, Tennant A. The use of the Visual Analogue Scale (VAS) in rehabilitation outcomes. J Rehabil Med. 2012;44(7):609–610. doi:10.2340/16501977-0999
   Web of Science ®Google Scholar
• Anderson G, Meyer D, Herrman CE, et al. Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. J Neurol. 2010;257(11):1917–1923. doi:10.1007/s00415-010-5779-x
   Web of Science ®Google Scholar
• Jaber A, Bozzato GB, Vedrine L, Prais WA, Berube J, Laurent PE. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol. 2008;8:38. doi:10.1186/1471-2377-8-38
   PubMed Web of Science ®Google Scholar
• Kleinschnitz C, Niemczyk G, Rehberg-Weber K, Wernsdörfer C. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): a prospective, observational study. Int J Mol Sci. 2015;16(7):15271–15286. doi:10.3390/ijms160715271
   PubMed Web of Science ®Google Scholar
• Halper J, Centonze D, Newsome SD, et al. Management strategies for flu-like symptoms and injection-site reactions associated with peginterferon Beta-1a: obtaining recommendations using the delphi technique. Int J MS Care. 2016;18(4):211–218. doi:10.7224/1537-2073.2015-042
   Google Scholar
• Kolb-Mäurer A, Sunderkötter C, Kukowski B, Meuth SG. An update on peginterferon beta-1a management in multiple sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists. BMC Neurol. 2019;19(1):130. doi:10.1186/s12883-019-1354-y
   Web of Science ®Google Scholar
• Balak DM, Hengstman GJ, Çakmak A, Thio HB. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Mult Scler. 2012;18(12):1705–1717. doi:10.1177/1352458512438239
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen K, Ramia N, et al. Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a Phase I, open-label crossover study in healthy volunteers. Ther Adv Neurol Disord. 2021;14:1756286420975227. doi:10.1177/1756286420975227
   Web of Science ®Google Scholar
• Filipi ML, Beavin J, Brillante RT, et al. Nurses’ perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis. Int J MS Care. 2014;16(1):55–60. doi:10.7224/1537-2073.2013-006
   Google Scholar
• Hendin B, Naismith RT, Wray SE, et al. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks. Patient Prefer Adherence. 2018;12:1289–1297. doi:10.2147/PPA.S157317
   Web of Science ®Google Scholar
• Centonze D, Fantozzi R, Buttari F, et al. Peg-IFN beta-1a pre-filled pen (Plegridy®) improves satisfaction in patients with relapsing-remitting multiple sclerosis who were dissatisfied with other subcutaneous interferons. Poster ID37 presented at European Charcot Foundation (ECF) Congress 2019; 21-23 November; 2019.; Baveno, Italy.
   Google Scholar